

(Sharecast News) - Cell engineering technology specialist MaxCyte announced a significant chief executive transition on Tuesday and updated its revenu...


(Sharecast News) - Cell engineering company MaxCyte announced its membership in the Alliance for mRNA Medicines (AMM) as a founding member on Thursday...


(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately report...


(Sharecast News) - Cell engineering specialist MaxCyte revised its full-year guidance downwards on Thursday based on its preliminary third-quarter rev...


(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.


(Alliance News) - MaxCyte Inc on Thursday said it expects revenue in the third quarter and for all of 2023 to fall from a year before, citing volatili...


(Alliance News) - MaxCyte Inc on Thursday reported an increased loss in the first half of 2023, as revenue fell while costs increased.